Analyst Price Targets — LGVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 29, 2024 6:05 am | Raghuram Selvaraju | H.C. Wainwright | $10.00 | $3.44 | TheFly | Longeveron price target lowered to $10 from $12 at H.C. Wainwright |
Latest News for LGVN
Longeveron (NASDAQ: LGVN - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability. Risk and Volatility Longeveron has a beta of
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned
China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs).
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript
Longeveron reported financial results for the year ended December 31, 2025 and provided a business update. Results from pivotal P2 trial anticipated 3Q26.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LGVN.
U.S. House Trading
No House trades found for LGVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.